Biomedical company Inventia Life Science has announced it will build a new advanced manufacturing hub in Sydney with support from the NSW Government's Jobs Plus Program.
The company said the support will go towards infrastructure to dramatically increase its current manufacturing capacity to support its international commercial expansion.
The company is currently transitioning from an initial soft-launch phase of RASTRUM 3D bioprinter and biomaterials to a full commercial scale-up.
Inventia said it has seen a strong international and domestic demand for RASTRUM from global pharmaceutical companies and research institutes.
Currently, four pharmaceutical companies use RASTRUM for drug development and meeting this demand will initiate flow-on growth across Inventia’s technical and commercial teams.
This new facility will enable Inventia’s manufacturing footprint to increase from roughly 430 square meters to 1,500 square meters. The new facility will include state-of-the-art laboratory facilities. It will be the headquarters for all of the company's Australian employees, which is expected to exceed 100 people by the end of this year.
Inventia’s founder and CEO Dr Julio Ribeiro said, “We are delighted by the support we have been given by the NSW Government. As a result of the Jobs Plus grant, we have been able to scale up our production capabilities, employ more highly skilled people including biologists, software and mechanical engineers and take this revolutionary technology to the world.
"Inventia's drop-on-demand 3D bioprinting technology is the most advanced and precise 3D printing of its kind in the world. It is well placed to consolidate Australia as a global leader in this field. These additional funds will help us cement Australia's position and expand our global presence.”